PJC 57.95 Piper Jaffray Companies $PJC Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
PJC 57.95 Piper Jaffray Companies $PJC Hit a 52 week high of 58.12 Closing the day 09:45 at 57.95 -0.58 -0.99% With a day low of 57.85 and a total volume of 2,751.

PJC Recent Posts: http://investorshangout.com/Piper-Jaffray-Com...PJC-52303/

PJC Piper Jaffray Companies Recent Headline News

Insider Trading Alert - PJC, SMCI And ARE Traded By Insiders
at The Street - Tue Nov 11, 10:30AM CST
Stocks with insider trader activity include PJC, SMCI and ARE
SMCI: 33.60 (-0.14), ARE: 82.83 (-0.65), PJC: 58.71 (+0.18)

Piper Jaffray Up 13.6% Since SmarTrend Uptrend Call (PJC)
Comtex SmarTrend(R) - Tue Nov 11, 9:25AM CST
SmarTrend identified an Uptrend for Piper Jaffray (NYSE JC) on October 23rd, 2014 at $51.93. In approximately 3 weeks, Piper Jaffray has returned 13.61% as of today's recent price of $59.00.
PJC: 58.71 (+0.18)

Investment Technology Group (ITG) Jumps: Stock Rises 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:32AM CST
Investment Technology Group Inc. (ITG) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
ITG: 19.68 (-0.11), PJC: 58.71 (+0.18), AI: 27.40 (+0.06), BGCP: 8.63 (+0.01)

Piper Jaffray Companies' (PJC) CEO Andrew Duff on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 23, 3:10PM CDT

PJC: 58.71 (+0.18)

NYSE stocks posting largest percentage increases
AP - Thu Oct 23, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at 1 p.m.:
CRS: 51.65 (+0.17), UFS: 41.63 (+0.90), CLV: 10.46 (+0.15), BBW: 18.22 (-0.20), PJC: 58.71 (+0.18), CLF: 10.87 (+0.11), MTRN: 38.70 (+0.27), XRS: 32.25 (+0.14), GPI: 88.62 (+1.39), BRP: 23.40 (-0.12), UIS: 27.89 (+0.23), SIX: 40.45 (+0.18), DF: 16.78 (+0.51)

Piper Jaffray beats by $0.46, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 7:04AM CDT

PJC: 58.71 (+0.18)

Piper Jaffray Companies Announces 2014 Third Quarter Results
Business Wire - Thu Oct 23, 7:03AM CDT
Piper Jaffray Companies (NYSE: PJC) today announced its financial results for the quarter ended September 30, 2014.
PJC: 58.71 (+0.18)

Piper Jaffray Companies to Hold Management Conference Call to Discuss 2014 Third Quarter Results
Business Wire - Wed Oct 15, 11:14AM CDT
Piper Jaffray (NYSE JC) announced today that it will release its 2014 third quarter results prior to the opening of the market on Thursday, October 23, 2014. The company will also hold a conference call to review the financial results at 9:00 a.m. ET (8:00 a.m. CT). Andrew S. Duff, chairman and chief executive officer, and Debbra L. Schoneman, chief financial officer, will host the call.
PJC: 58.71 (+0.18)

Can Schwab Beat Wall St. For 5 Quarters In A Row?
at Investor's Business Daily - Mon Oct 13, 3:12PM CDT
Recent market choppiness has swamped Charles Schwab along with other brokers. With the waters muddied, it's not clear whether Schwab's earnings will be strong enough to meet or beat Wall Street expectations. The discount broker reports third-quarter...
RJF: 57.25 (-0.24), PJC: 58.71 (+0.18), AMP: 129.98 (-0.38), SCHW: 28.87 (+0.02)

Different is the New Cool, According to Piper Jaffray Survey of 7,200 Teens
Business Wire - Wed Oct 08, 10:00AM CDT
Piper Jaffray (NYSE: PJC) has completed its 28th semi-annual Taking Stock With Teens market research project, which indicates increased spending across categories despite decreased optimism about the economy.
PJC: 58.71 (+0.18)

Uptrend Call Working As Piper Jaffray Stock Rises 23.0% (PJC)
Comtex SmarTrend(R) - Thu Sep 25, 4:43PM CDT
SmarTrend identified an Uptrend for Piper Jaffray (NYSE JC) on April 25th, 2014 at $44.54. In approximately 5 months, Piper Jaffray has returned 22.96% as of today's recent price of $54.76.
PJC: 58.71 (+0.18)

Piper Jaffray Hits 52-Week High on Capital Market Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 1:58PM CDT
Shares of Piper Jaffray Companies (PJC) crafted a new 52-week high, touching $56.40 on Sep 17.
MRCC: 14.01 (-0.12), PJC: 58.71 (+0.18), AI: 27.40 (+0.06), MC: 34.49 (-0.46)

Piper Jaffray Shares Up 27.0% Since SmarTrend's Buy Recommendation (PJC)
Comtex SmarTrend(R) - Thu Sep 18, 11:04AM CDT
SmarTrend identified an Uptrend for Piper Jaffray (NYSE JC) on April 25th, 2014 at $44.54. In approximately 5 months, Piper Jaffray has returned 26.96% as of today's recent price of $56.54.
PJC: 58.71 (+0.18)

Schwab's August DATs Witness Marginal Y/Y Decline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 4:50PM CDT
Schwab (SCHW) recorded Daily Average Trades of 460,000 for Aug 2014, reflecting a decline of 1% from the prior-year month and remaining same as that of the prior month.
PJC: 58.71 (+0.18), AI: 27.40 (+0.06), MC: 34.49 (-0.46), SCHW: 28.87 (+0.02)

CIT Group Grows Inorganically: Right Time to Buy the Stock? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 10:40AM CDT
CIT Group Inc. (CIT) has come a long way since its emergence from bankruptcy in 2009. The company is presently focused on growing inorganically.
PJC: 58.71 (+0.18), AI: 27.40 (+0.06), MC: 34.49 (-0.46), CIT: 49.58 (+0.39)

E*TRADE Financial (ETFC) August DARTs Descend 5% Q/Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:40AM CDT
Online brokerage firm, E*TRADE Financial Corporation (ETFC) reported a decline in its Daily Average Revenue Trades (DARTs) for Aug 2014.
PJC: 58.71 (+0.18), ETFC: 22.67 (-0.44), AMTD: 35.11 (-0.27), SCHW: 28.87 (+0.02)

How Will Visa (V) Stock Respond To These Coverage Initiations?
at The Street - Tue Sep 16, 7:44AM CDT
Visa (V) stock is up in pre-market trade after the financial company had coverage initiated at Sterne Agee, Bernstein and Piper Jaffray (PJC).
V: 251.61 (+1.88), PJC: 58.71 (+0.18)

Morgan Stanley to Phase Out Managed Mutual Fund Platform - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:50PM CDT
Morgan Stanley (MS), the world's largest seller of managed accounts, is phasing out a managed mutual fund program.
PJC: 58.71 (+0.18), AI: 27.40 (+0.06), BAC: 17.23 (-0.09), MS: 35.95 (+0.16)

Capital One's Expenses on Downward Trail, Revenues Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 5:25PM CDT
Capital One exhibits prudent expense management and remains strong in its Credit Card business. However, slump in overall revenues remains a major concern.
COF: 81.55 (-0.63), PJC: 58.71 (+0.18), HSBC: 50.18 (-0.39), AI: 27.40 (+0.06)

Piper Sandler Companies (PIPR) Stock Research Links

PIPR Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 9

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 3

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 6

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 4

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Soleno Therapeutics Celebrates FDA Approval of VYKAT XR for PWS

Updated Category News Views 420

Soleno Therapeutics Announces FDA Approval for VYKAT XR Soleno Therapeutics, Inc. (NASDAQ: SLNO), a notable biopharmaceutical company, has made a significant announcement regarding the U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets. This new treatment targets hyperphagia in individuals aged four and older...

Continue Reading
aTyr Pharma Faces Legal Challenges: Investors Urged to Act

Updated Category News Views 173

aTyr Pharma's Legal Situation and Its Implications Recent developments surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) have caught the attention of investors, particularly as the company faces significant legal challenges. The situation arose from a steep decline in share value triggered by disappointing results from a key clinical trial. This decline, marked by an...

Continue Reading
Primo Brands Boosts Share Repurchase Program by $50 Million

Updated Category News Views 145

Primo Brands Boosts Share Repurchase Program Primo Brands Corporation (NYSE: PRMB) is excited to announce a significant increase in its share repurchase program. This decision, made by the Board of Directors, involves raising the repurchase authorization by $50 million, bringing the total program authorization to an impressive $300 million. This enhancement in the share...

Continue Reading
GOTRAX Partners with RSMG Select to Inspire Youth Movement

Updated Category News Views 83

GOTRAX Teams Up with RSMG Select for Youth Development GOTRAX has embarked on an inspiring journey through its partnership with RSMG Select, aimed at nurturing not just young athletes but the community at large. The collaboration has transformed the experience for youth participating in futsal, allowing for significant growth and empowerment beyond the typical sports...

Continue Reading
Zenas BioPharma Celebrates Major Milestones in Q3 2025

Updated Category News Views 245

Zenas BioPharma Celebrates Major Milestones in Q3 2025 - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end. - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS). - Secured development and commercialization rights for three...

Continue Reading